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p53 is a thermodynamically unstable protein containing a
conformationally flexible multiprotein docking site within the
DNA-binding domain. A combinatorial peptide chip used to
identify the novel kinase consensus site RXS(K/D) led to the
discovery of a homologous phosphorylation site in the S10
-strand of p53 at Ser269. Overlapping peptide libraries con-
firmed that Ser269 was a phosphoacceptor site in vitro, and
immunochemical approaches evaluated whether p53 is phos-
phorylated in vivo at Ser269.Mutation or phosphorylation of p53
at Ser269 attenuates binding of the p53-specific monoclonal
antibodyDO-12, identifying an assay formeasuringSer269 phos-
phorylation of p53 in vivo. The mAb DO-12 epitope of p53 is
masked via phosphorylation in a range of human tumor cells
with WT p53 status, as defined by increased mAb DO-12 bind-
ing to endogenous p53 after phosphatase treatment. Phospho-
Ser269-specific monoclonal antibodies were generated and used
to demonstrate that p53 phosphorylation is induced at Ser269
after irradiation with kinetics similar to those of p53 protein
induction. Phosphomimetic mutation at Ser269 inactivated the
transcription activation function and clonogenic suppressor
activity of p53. These data suggest that the dynamic equilibrium
betweennative andunfolded states ofWTp53canbemodulated
by phosphorylation of the conformationally flexible multipro-
tein binding site in the p53 DNA-binding domain.
Exposure to a wide variety of genotoxic and metabolic
stresses leads to the activation of the p53 tumor suppressor
protein, a sequence-specific DNA-binding protein and stress-
activated transcription factor that controls and coordinates the
expression of a battery of genes involved in transient growth
arrest, DNA and cellular repair, and/or apoptosis (1). The func-
tion of the p53 protein is regulated post-translationally by
enzymes that catalyze p53 ubiquitination, acetylation, and
phosphorylation. In the absence of stress, the specific activity of
p53 is suppressed by the action of E3 ubiquitin ligases like
MDM2 that promote proteasomal degradation of the protein
(2). In response to stress signals like DNA damage, this degra-
dation program is suppressed, and sets of protein kinase path-
ways, notably ATM, trigger activation of the protein.
The mechanisms of p53 activation by phosphorylation at the
most evolutionarily conserved phosphoacceptor sites has been
assigned both biochemically and genetically. The phosphoaccep-
tor sites in the p53 transactivation domain are the most highly
conserved between vertebrates and invertebrates: phosphoryla-
tion of p53 at Ser20 stabilizes the interaction with acetyltrans-
ferases like p300 and in turn stimulates DNA-dependent acetyla-
tion (3,4);phosphorylationatSer15 canstimulateCBPbindingand
p53 acetylation (5); and phosphorylation at Thr18 can both stabi-
lize p300 binding and reduceMDM2 binding (4, 6). The stabiliza-
tion of p300 relates to the conversion of intrinsically unstructured
activation motifs in p53 to a more helical character with a higher
affinity for p300 (7). Mice with mutations at the equivalent Ser20
residue develop spontaneous B-cell lymphomas (8), and Ser15
mutant transgenes develop spontaneous late onset lymphoma (9).
The Ser392 phosphoacceptor site in the C-terminal domain of p53
is the secondmost highly conserved class of phosphoacceptor site
but only within vertebrates. Increased phosphorylation of p53 at
the Ser392 site occurs in vivo after UV and ionizing radiation (10,
11), and this stimulates the sequence-specific DNA-binding func-
tion of p53 (12). Phosphorylation of p53 at Ser392 enhances the
stability of the p53 tetramerization domain (13), and phosphomi-
metic mutation at codon 392 results in enhanced thermostability
of the p53 tetramer (14), providing biophysical evidence for con-
formational changesof thisphosphorylationonp53.Genetic stud-
ies in mice have shown that mutation of the CK2 site results in
enhanced skin or bladder cancer in response to UV damage or
carcinogen exposure (15, 16), andmouse embryo fibroblasts from
such transgenic mice also have an attenuated p53 transcriptome
(17). Further, the enhanced phosphorylation of p53 in the basal/
stem cells of UV-irradiated human skin (11) is attributable to the
transcriptional activation of ATMbyNp63 (18). Although these
biochemical andgenetic studies provide aparadigm forhowphos-
phorylation can regulate p53 protein function at the most highly
conserved phosphorylation sites, the effects of many other cova-
lent modifications on p53, including over 12 other phosphoryla-
tion sites andmethylation sites, are only just now being defined at
the biochemical and genetic level.
There is growing evidence that protein-protein interactions,
although driven by globular domains, are regulated by intrinsi-
cally disordered motifs or linear peptide docking motifs (19).
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These linear motifs might acquire structure upon binding to
target protein or may themselves induce a specific structure by
stabilizing the target protein in a specific conformation. p53
protein is a case in point; it is a thermodynamically unstable
protein that has a large set of peptide-docking sites within its
structural or unstructured domains that drive key protein-pro-
tein interactions that regulate its function, including ubiquiti-
nation and phosphorylation (20). The E3 ubiquitin ligase
MDM2 is a prime example of this because at least two distinct
linear peptide domain interaction sites are required forMDM2
to catalyze p53 ubiquitination. The primary binding site of
MDM2 for p53 occurs at a peptide motif (FXXXWXXL) in the
intrinsically unstructured N-terminal domain of p53 through
an interaction with the N-terminal hydrophobic pocket of
MDM2 (21). The second MDM2 interaction site occurs
through an interaction between the MDM2 acidic domain and
a motif (SXXLXXGXXXF) in the conformationally flexible
DNA-binding domain in p53 within the S9-S10 loop/S10
-sheet (22). This latter site forms the ubiquitination signal for
E2-E3 (MDM2)-catalyzed ubiquitin transfer to the p53 tet-
ramer (23). This site is notable in that it is also a site of pro-
nounced conformational flexibility that reveals and “opening”
or destabilization of the p53 DNA-binding domain (24). This
conformationally-flexible site is also notable in that it forms a
docking site for the distinct class of protein kinases that phos-
phorylate p53 in its transactivation domain (25, 26), indicating
that this region forms a multiprotein interaction site.
In order to determinewhether p53 is directly phosphorylated
at this multiprotein docking site, thus providing another layer
of post-translational regulation, we took advantage of a tool
involving kinase substrate profiling to define the linear interac-
tion motifs that direct enzyme specificity and substrate utiliza-
tion. Here we used chip peptide array technology to expand
substrate utilization of the calmodulin kinase family members
to define potential physiological phosphoacceptor consensus
sites using peptides from naturally occurring proteins. Indeed,
PepChip technology has been used to successfully characterize
the complex changes that occur within the epithelial esopha-
geal kinome during the early transitional stages of carcinogen-
esis (27) and map the cellular phosphoproteome (28). After
delineation of a novel consensus phosphoacceptor site coupled
to homology searches for similar motifs in the p53 DNA-bind-
ing domain, we identified a novel phosphorylation site in the
S10 -sheet region of p53 at Ser269. This region is notable in
being (i) a site of conformational flexibility in mutant gain-of-
function p53 (24); (ii) the ubiquitin signal forMDM2-mediated
ubiquitination of p53 (23); and (iii) a docking site for a range of
protein kinases that phosphorylate the transactivation domain
of p53 (25). A range of approaches were used to demonstrate
that Ser269 phosphorylation can occur on endogenousWT p53
in cells and that phosphomimeticmutation at codon 269 results
in the production of inactiveWT p53. An accompanying paper
describes the biophysical basis for p53 inactivation by phos-
phorylation of p53 at Ser269 and involves primarily increases in
the thermoinstability of the core DNA-binding domain of p53.
These data highlight the existence of a novel kinase pathway
that can regulate the dynamic range of conformations in WT
p53 and that can produce a mutant-like conformation on WT
p53.
MATERIALS ANDMETHODS
Reagents and Plasmids—N-terminally tagged biotinylated
peptides with an SGSG spacer were obtained fromMimotopes
(Carlton, Australia). Anti-p53 antibodies were DO-1, DO-12,
PAb240, PAb1620, CM-1, Ab-1 (anti-p21, Cell Signaling), and
2A10 (anti-Mdm2). pcDNA 3.1 p53 and pCMV-Mdm2 plas-
mids were described (23). The p53 gene was cloned into the
pExpr vector (IBA Systems), generating a construct with an
N-terminal streptavidin tag. Single amino acid mutations were
introduced into wild type p53 at Ser269 according to the
QuikChange site-directed mutagenesis kit (Stratagene) using
pcDNA 3.1 p53, pExpr p53, and pRSET p53 DNA core domain
as templates, and the following oligonucleotides were used for
mutagenesis (underlined): p53 S269A, 5-g gga cgg aac gcc ttt
gag gtg cg-3 (forward primer) and 5-cg cac ctc aaa ggc gtt ccg
tcc c-3 (reverse primer); p53 S269D, 5-ctg gga cgg aac gac ttt
gag gtg cg-3 (forward primer) and 5-cg cac ctc aaa gtc gtt ccg
tcc cag-3 (reverse primer).
Kinase Assays—PepChip kinase slides were obtained from
Mimotopes Pty. Ltd. Protein kinases were mixed with 10
MATP and 300Ci/ml [-33P]ATP (3000Ci/mmol) in 50mM
Hepes, pH 7.5, 10 mM MgCl2, 1 mM dithiothreitol, 0.8 mM
EDTA, 5% glycerol, and 0.01% Brij-35, in the presence or
absence of 75 M Box V peptide (30). The reaction mixtures
were spotted onto the PepChip slide and covered before they
were transferred into a humidified chamber and incubated at
30 °C for 3 h. The PepChip slides were washed once with phos-
phate-buffered saline containing 1% Triton X-100 and twice
with 2 M NaCl containing 1% Triton X-100. [-33P]ATP incor-
poration was visualized using a PhosphorImager (Storm 840,
Amersham Biosciences). Peptide sequence information per-
taining to the individual spots was obtained by overlaying the
image with the reference grid provided by Pepscan Systems
B.V. (Lelystad,Netherlands). Peptide kinase reactionswere car-
ried out as described previously (30), using 150 ng of purified
recombinant protein kinase and 1 g of peptide substrate.
Peptide ELISA—Biotinylated unphosphorylated and phos-
phorylated peptides were captured onto ELISA wells coated
with streptavidin and blocked with 3% BSA in PBS-Tween as
described previously (31).
Cell Culture, Transfection, and Analysis—All tissue culture
medium was obtained from Invitrogen and was supplemented
with 10% fetal bovine serum. H1299 cells were cultured in
RPMI 1640 medium; A375, HEK-293, and MCF-7 cells were
cultured in DMEM, and HCT-116 p21 null cells were grown in
McCoy’s medium. Cells were harvested and lysed using urea
lysis buffer as described previously (30) unless otherwise stated.
For luciferase assays, H1299 cells were transfected the follow-
ing day with 30 ng of pCMV Renilla and 70 ng of either p21-luc
or Bax-luc and plasmids encoding p53 wild type, p53S269A, or
p53S269D. Cellswere lysedwith lysis buffer according to the dual
luciferase assay kit (Promega), and luciferase activity was quan-
tified using a luminometer (Fluoroskan Ascent FL). For cellular
fractionation, cells were treated with 10 J cm2 UVC and grown
for a further 6 h at 37 °C prior to fractionation using the S-PEK
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subcellular fractionation kit (Calbiochem). For immunopre-
cipitation, cell lysates (100 ng) were precleared with protein G
beads (Sigma) for 1 h before incubation with 1 g of DO-1,
PAb1620, or PAb240 at 4 °C. For immunoprecipitation of
endogenous phospho-Ser269 p53, mouse monoclonal antibod-
ies were preadsorbed to protein G beads overnight before incu-
bation with precleared lysates and washed and eluted as above.
For clonogenic survival assays, H1299 cells were transfected
with pcDNA p53 constructs, and colonies were selected using
Geneticin as described previously (32).
Phosphatase Treatment of Nitrocellulose Membranes—Ni-
trocellulose membranes were incubated in 50 mM Tris, pH 7.5,
5 mMDTT, 0.1 mM EDTA, 2 mMMnCl2, and 80 units of -pro-
tein phosphatase (Sigma) for 1 h at 30 °C (33). The degree of
epitope unmasking was determined by quantifying the band
intensity using Scion Image software.
RESULTS
In Vitro Kinase Screens Identify a Novel Phosphoacceptor Site
at Ser269 in the DNA-bindingDomain of p53—Because protein-
protein interactions are driven in part by intrinsically disor-
dered linear peptide motifs, we previously screened a peptide
library withMDM2 protein to acquire novelMDM2 consensus
peptide binding motifs. These peptide motifs were scanned for
homology to sites in the tumor suppressor protein p53, thus
identifying a secondMDM2 binding site in the p53 DNA-bind-
ing domain (22, 35). Similarly, in this report, we screened
selected kinase superfamily members using a kinase-peptide
array that contains 192 naturally occurring phosphoacceptor
sites to define a broader consensus site for protein kinases.
These consensus sites in turn could be scanned for homology to
motifs in p53 thatmight reveal novel p53 phosphorylation sites.
When kinases are screened in this assay, a range of peptide
substrates were identified (Fig. 1A shows a representative
screen using DAPK-1 (i.e. DAPK core kinase domain)). DAPK
targeted 68 of the 192 peptides on the chip (Fig. 1A), and these
peptides covered a wide range of cellular proteins (supplemen-
tal Table I). Although the library of peptides on the chip does
not comprehensively represent the diversity of the human pro-
teome and known substrates of DAPK, such as p21, p53, and
myosin light chain, are not represented, there were several pep-
tide hits that were in keeping with the function of DAPK in
regulating the cytoskeleton, such as vimetin. The majority of
peptides targeted by DAPK core contained a serine residue as
the phosphoacceptor (52 of 68 peptides), whereas only a small
proportion contained a threonine as the phosphoacceptor res-
idue (9 of the 68 phosphorylated peptides). Several peptides
contained more than one potential phosphoacceptor site (e.g.
peptide 1, 4, or 8 (LRRSSSVGY, PGGSTPVSS, or KTTAS-
TRKV)), and in such cases, the central residue was taken as the
phosphoacceptor. Analysis of the relative abundance of the var-
ious amino acid residues within the peptides targeted by DAPK
(Table 1) showed a strong selection for peptides with leucine
and lysine residues at the4-position and a strong preference
for basic residues, such as lysine and arginine, at the 3- and
2-positions. This observation is in keeping with previous
studies that show that DAPK is a basophilic kinase and prefers
substrates containing a high proportion of basic residues, such
as lysine and arginine, upstream of the phosphoacceptor site
(30, 36, 37). The most prominent residues at the 1-position
were more non-polar/hydrophobic residues, such as proline,
glycine, and alanine. Downstream of the phosphoacceptor ser-
ine, there was a high prevalence of basic residues, such as argi-
nine and lysine, as well as proline residues at the 1- and
2-positions; however, there was also an increased abundance
of valine and phenylalanine residues. This is also in keeping
with previous findings that showed that DAPK has a strong
preference for hydrophobic leucine, valine, and phenylalanine
residues downstream of the phosphorylated serine (36, 37).
There was also a positive preference for alanine residues at the
3-position and acidic residues, such as glutamic and aspartic
acid, at 2 and 3. The relative abundance of the various
amino acids was tallied to generate a consensus sequence, and
the simplest derived consensus for DAPK substrates was deter-
mined to be (K/L)(R/K)R(P/G/A)S(P/V/F)(R/K/D)(A/E/P)(K/
S/P) (Table 1). The minimal consensus site of RXSF(D/K)
obtained (Fig. 1B) was then screened for homology to p53 and
identified a site in the conformationally flexible motif,
267RNSFE271.
This motif in p53 is notable in that it is one site of three
conformational flexible epitopes that are “cryptic” on WT p53
but “exposed” on mutant p53 in human cancers (24). The bio-
physical basis for this equilibrium is now thought to be a func-
tion of the intrinsic thermodynamic instability of the core
DNA-binding domain of p53 that is further destabilized by
mutation (38). This allostery operating in p53 is now thought to
be consistent with the ensemble model of allostery (39), where
proteins exist in a range of conformational states under regu-
FIGURE 1. Pepchip kinase array screen identifies a novel phosphoaccep-
tor site in theDNA-binding domain of p53. A, in vitro kinase consensus site
definition using peptide arrays. A Pepchip array (total of 192 peptides) was
incubated with 30 ng of DAPK core and [-33P]ATP for 3 h at 30 °C, and phos-
phorylated peptides were detected by storage phosphor screen. The array is
arranged inagrid from1 to4 in the yaxis and1and2 in the xaxis (induplicate).
B, consensus sites for protein kinases. Phosphorylated peptides from A (sup-
plemental Table I) were analyzed as indicated in Table 1 to develop the con-
sensus site summarized (RXSF(D/K)), whichmatches the Ser269 site in the p53
tumor suppressor protein.
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latable equilibrium. This motif in p53 also forms the second
MDM2 binding site, whose mutation stimulates p53 ubiquiti-
nation in cells (22) andwhich forms the ubiquitination signal in
the allosteric MDM2-mediated ubiquitination of p53 (23, 40).
This region also forms docking sites for a range of protein
kinases that catalyze phosphorylation of p53 in its transactiva-
tion domain (reviewed in Figs. 2 and 11). The specific contacts
for these many binding proteins like CHK2, MDM2, and CK1
are distinct, as highlighted in Fig. 2. This is consistent with
recent data showing that small linear and intrinsically unstruc-
tured peptidemotifs, such as those in theC terminus of p53, can
interact with a target protein through distinct and specific
amino acid side chain contacts (41). Thus, this Ser269 site on
p53 can be solvent-exposed, is in dynamic equilibrium, and is a
potential phosphoacceptor site that could have pleotropic
effects on p53 folding and function.
In addition to the potential phosphoacceptor site at Ser269
defined from the homology screen above, the conformationally
flexible motif of p53 contains two further, putative phosphoac-
ceptor sites at Ser260 and Ser261 (Fig. 2). Peptides derived from
this region of p53 containing Ser269 or Ser260/Ser261 phos-
phoacceptor sites (Fig. 3A) were used in kinase assays to deter-
mine whether these serine residues are bona fide phosphoac-
ceptor sites. Only peptides containing the Ser269 site can
function as substrates for DAPK (Fig. 3B, lanes 5–9 versus lanes
1–4), consistent with the kinase-peptide scan in Fig. 1, where a
bulky hydrophobic residue flanking the phosphoacceptor site
plays a role in phosphorylation. By contrast, another kinase we
evaluated (Chk1) is a relatively poor kinase toward peptides
containing the Ser269 phosphoacceptor site, whereas it demon-
strates better specificity for the peptide with double phos-
phoacceptor sites at Ser260/261 (Fig. 3C, lanes 2–5 versus lanes
6–9). Together, these data indicate that the flexible linker of
p53 has a phosphoacceptor site at Ser269 in vitro that shares
homology with members of the calcium-calmodulin kinase
superfamily that can target the RXSF(D/E) motif.
In Vivo Evidence for p53 Phosphorylation at Ser269 Defined by
DO-12 mAb Epitope Masking—We next evaluated whether in
vivo evidence could be acquired for Ser269 phosphorylation. If
so, this would make biochemical and cellular analysis of Ser269
modification more physiologically relevant. Two approaches
were taken to examine Ser269 phosphorylation in cells: (i)
epitope masking using a monoclonal antibody whose binding
site overlaps with Ser269 and (ii) phosphospecific antibody gen-
eration to phospho-Ser269. A notable feature of the conforma-
tionally flexible motif containing Ser269 is that it overlaps with
the DO-12 monoclonal antibody epitope (Fig. 2) (24); this
epitope (amino acids 255–270) is normally constrained in wild
type native p53 or whenwild type p53 is bound toDNA, but the
monoclonal antibody can bind to and immunoprecipitate
mutant p53 due to conformational changes that expose the
epitope. This change in epitope exposure due to p53mutations
is thought to be due to the changes in the dynamic range in p53
conformational states, according to the ensemble model of
allostery.
The Ser269 residue is located at the end of the DO-12 epitope
(amino acids 255–270) (Fig. 2). Key phosphorylation sites on
p53 are often found within the epitopes of several monoclonal
antibodies (such as DO-1 (calcium-calmodulin kinase super-
FIGURE 2. The multiprotein docking sites within the p53 DNA-binding
domain.Protein-protein contacts in the conformationally flexibleubiquitina-
tion signal from theDNA-bindingdomainof p53. The key residues involved in
MDM2, Chk2, and CK1a binding (arrows) and the contact sites for the DO-12
monoclonal antibody (green) are highlighted. The bottom panel indicates the
positioning of key residues in the region known to influence p53 stability.
TABLE 1
Quantifying the abundance and positioning of the amino acid residues within the DAPK peptide targets (data derived from supplemental
Table I)
The derived consensus sequence is as follows: (K/L)(R/K)R(P/G/A)S(P/F/V)(R/K/D)(A/E/P)(K/S/P).
4 3 2 1 Phosphoacceptor site 1 2 3 4
Ser 6 5 2 52 5 6 2 8
Thr 3 4 1 9 4 2 4 6
Tyr 1 7 1
Lys 24 14 4 3 5 9 6 9
Leu 23 4 5 5 4 4 2 4
Arg 2 22 20 2 2 13 3 3
Pro 9 4 4 17 11 4 7 7
Gly 5 7 9 4 2 5 3
Ala 1 8 2 4 12 3
Val 1 1 2 7 3 4 3
Ile 2 2 3 2 3 4
Asp 1 3 4 5 7 3 1
Glu 2 3 2 4 5 8 5
Asn 2 1 2 1
Gln 2 2 5 2 2 4 1 4
Phe 1 4 7 1 2 4
Trp 1 3 1 1 1
Met 2 2 1 2
His 1 2
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family site at Ser20) (31), PAb421
(PKC site at Ser371/376) (42), ICA-9
(CK2 site, Ser392), or MDM2 (2A10,
ATM site at Ser395)) (43), and
monoclonal antibody binding to
these epitopes is masked by phos-
phorylation. As such we evaluated
whethermutation or substitution of
p53 at Ser269 attenuated DO-12
monoclonal antibody binding. If so,
this would provide an indirect assay
for determining whether phosphor-
ylation occurs at Ser269 on endoge-
nous p53 in vivo. DO-12 mAb bind-
ing to peptides derived from this
region of p53 confirmed that Ser269
and Phe270 comprise a portion of
the DO-12 epitope (Fig. 4A), raising
the possibility that Ser269 phosphor-
ylation could affect mAb-DO-12
binding. Phosphopeptides were
generatedwithin theDO-12 epitope
that contain phosphate at Ser269,
Ser261, or Ser260. When DO-12
binding to these substituted pep-
tides was measured, only Ser269
phosphorylation attenuated the
binding of the monoclonal antibody
(Figs. 4B and 5). By contrast, Ser261
or Ser260 phosphopeptides actually
exhibited elevated binding stability
toward DO-12 (Fig. 4B). Mutagene-
sis of codon 269 in full-length p53 to
alanine or the phosphomimetic
aspartate resulted in masking of the
DO-12 epitope (Fig. 5, A and B),
indicating that the integrity of
Ser269 is required for DO-12 to bind
stably. As a control, binding of
another conformationally sensitive
p53 monoclonal antibody, PAb240
(epitope 209–214) (44), was exam-
ined, and PAb240 binding was not
inhibited by mutation of codon 269
(Fig. 5C), indicating that mutation
and phosphorylation at Ser269 spe-
cifically masks the DO-12 epitope.
A range of cell lines containing
wild type p53 protein (including
malignant melanoma (A375), mam-
mary adenocarcinoma (MCF-7),
colorectal carcinoma (HCT-116),
and human embryonic kidney cells
(HEK-293)) were lysed in denatur-
ing urea buffer to preserve endoge-
nous p53 phosphorylation sites, and
total p53 protein levels were mea-
sured (Fig. 6A, lanes 1–4). Immuno-
FIGURE 3. The multiprotein docking peptide from the ubiquitin signal in the p53 DNA-binding domain
contains an in vitro phosphoacceptor site. A, overlapping peptides corresponding to the conformationally
flexible ubiquitination signal (with Ser260/261 phosphoacceptor sites in peptides 1–5 or Ser269 phosphoaccep-
tor site in peptides 5–9) were incubated in kinase reactions containing [-32P]ATP and either DAPK core (B) or
Chk1 (C) for 30min at 30 °C. Reaction products were resolved via 20% SDS-PAGE and dried, and phosphopep-
tides were visualized by a PhosphorImager (highlighted by arrows). The intensity of peptide phosphorylation
was quantified and normalized to kinase autophosphorylation and is expressed below each panel.
FIGURE 4. Attenuation of DO-12 epitope binding by Ser269 phosphorylation. A, DO-12 binding to the p53
DNA-binding domain. The region bound by the DO-12 monoclonal antibody was mapped by ELISA using
overlapping peptides derived from the DNA-binding domain of p53 (A, right). B, serine 269 phosphorylation
attenuates DO-12 binding. The effect of phosphorylation on the binding affinity of DO-12 to peptides (amino
acids 255–270of humanp53) derived from theDNA-bindingdomainof p53wasdefinedby ELISA and is shown
as a functionofDO-12 antibody titration. Thepeptide sequences andmodifications at serine 260, serine 261, or
serine 269 are shown below. R.L.U., relative light units. Error bars, S.D.
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blotting for total p53 protein levels demonstrated that compa-
rable levels of p53 protein were detected in A375, MCF-7, and
HCT-116 cells (Fig. 6A, lanes 1, 2, and 4), with significantly
greater levels of p53 protein detected in HEK-293 cells (Fig. 6A,
lane 3). By contrast, although a significant pool of DO-12-reac-
tive p53 was detected in HEK-293 cells, only faint bands corre-
sponding to p53 protein were detected in MCF-7, A375, and
HCT-116 cells (Fig. 6B, lanes 1–4). Because phosphorylation or
mutation at Ser269 can attenuate DO-12 antibody binding, we
hypothesized that reductions in mAb-DO-12 binding to p53 in
these cell lines might be due to phosphorylation masking the
epitope. To examine this, nitrocellulosemembranes were incu-
bated with -protein phosphatase, as described previously (33),
to remove any potential phosphate groups from the p53 protein
prior to immunoblotting with DO-12. After phosphatase treat-
ment, a significant increase in the intensity of the DO-12-reac-
tive p53 protein pool was observed in HEK-293, MCF-7, and
HCT-116 cell extracts (Fig. 6C). The reactivity of the p53
monoclonal antibody DO-1 did not change under these condi-
tions (data not shown). These data suggest that DO-12-sensi-
tive phosphorylation of p53 can be detected in a substantial
pool of the total p53 protein (see ratios of DO-12/DO-1 below
the lanes in Fig. 6B).
To further analyze in which cellular compartment p53 phos-
phorylation occurs at serine 269, as defined by DO-12 epitope
masking, lysates were isolated from MCF7 cells into cytosol,
membrane, and nuclear compartments (Fig. 7A). MCF7 cells
were used because this cell line has themost evidence of epitope
masking of endogenous p53 protein and is a standard cell line
used to study the DNA damage-induced p53 pulse (45). The
disadvantage of this methodology compared with the urea
denaturing method (Fig. 6) is that it uses non-denaturing buff-
ers that could liberate phosphatases and result in dephosphor-
ylation of p53 protein in the crude lysate. Nevertheless, differ-
entially extracted lysates defined as F1–F3 (Fig. 7A) were
acquired from MCF7 cells and immunoblotted for total p53
(Fig. 7B, lanes 1–3), for DO-12-reactive p53 (Fig. 7C), and for
DO-12-reactive p53 after phosphatase treatment (Fig. 7D, lanes
1–3). The total p53 protein was distributed into all three com-
partments shown (Fig. 7B, lanes 1–3) with little evidence of
DO-12-reactive p53 protein (Fig. 7C, lanes 1–3). This is con-
sistent with the data acquired using denaturing urea lysis (Fig.
6) and suggests that the buffers used do not permit dephos-
phorylation of the DO-12 epitope. DO-12-reactive p53 protein
could not be detected after phosphatase treatment of blots pre-
sumably because of the large dilu-
tions used in the chemical fraction-
ations (Fig. 7A) relative to whole cell
denaturing lysis buffer (Fig. 6). As
such, we also evaluated whether
DNA damage changes DO-12
epitope masking of p53 and in
which compartment this occurred.
In response to irradiation at doses
that activate p53 (data not shown),
there is an increase in p53 protein in
the nuclear fraction (Fig. 7B, lane 6
versus lanes 1–5), consistent with
previous reports that endogenous
p53 protein is largely stored in cyto-
solic fractions and is transported
into the nucleus after DNA damage
by a dynein-dependent pathway
(46). Under conditions where p53
protein is stabilized by irradiation,
we could detectDO-12-reactive p53
protein in the nucleus (Fig. 7C, lane
6 versus lanes 1–5), and this was
increased by phosphatase treatment
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of the immunoblots (Fig. 7D, lane 6 versus lanes 1–5). The load-
ing controls for the subcellular fractionation are highlighted in
Fig. 7, E–H. These data suggest that p53 can be phosphorylated
in the basal state in the DO-12 epitope but that DNA damage
induces a mixed pool of DO-12-reactive (i.e. non-phosphory-
lated) and DO-12-non-reactive p53 protein (i.e. phosphory-
lated).
In Vivo Evidence for p53 Phosphorylation at Ser269 Defined by
the Use of Novel Phosphospecific Ser269 mAbs—Although phos-
phatase-sensitive epitope masking of p53 has been a standard
method of defining phosphorylation of p53 at some sites, phos-
phospecific antibodies are the more generally useful tool now
used tomeasure steady-state levels of a post-translationalmod-
ification. We have previously generated phosphospecific
monoclonal antibodies as tools for investigating p53 phos-
phorylation in vivo (47), including Ser392 and Ser315 (48, 49). A
panel of phosphospecificmonoclonal antibodies was generated
to phospho-Ser269-containing peptides that demonstrated
specificity for the peptide from the MDM2 ubiquitination sig-
nal (LGRNpSFEVR, where pS represents phosphoserine) (Fig.
8A). An alanine scan phosphopeptide screen indicated that the
phospho-Ser269-specific monoclonal antibodies displayed a
requirement for key amino acids surrounding the phospho-
serine residue (Fig. 8A, i–iii). We used these monoclonal anti-
bodies to determine whether similar evidence could be
acquired for radiation-induced Ser269 phosphorylation of p53
protein that correlated with DO-12 epitope masking.
When cells were exposed to UV or x-ray radiation, the stan-
dard induction of p53 protein could be confirmed (Fig. 8B).
Immunoprecipitation of p53 with a monoclonal antibody and
direct blotting with a polyclonal antibody could confirm that
the immunoprecipitation assay could be used to measure
increases in p53 protein levels (Fig. 8C). When the monoclonal
antibody 2.1was used under the same conditions, an increase in
Ser269-phosphorylated p53 protein could be detected whether
using x-ray or UV irradiation (Fig. 8D). A time course mea-
suring increases in p53 protein levels (Fig. 8E) or phospho-
Ser269 p53 protein levels (Fig. 8F) indicated that the kinetics of
induction of p53 phosphorylation at Ser269 was similar to that
of total p53 protein. Thus, using either a mAb epitope masking
assay or direct phospho-Ser269-specific mAb binding assay, we
present evidence that phosphorylation at Ser269 can occur in
vivo and that it increases in response to DNA damage.
An Inactivating Function for Ser269 Phosphorylation of p53—
In order to propose a function for Ser269 phosphorylation of
p53,mutagenesis was performed to produce a phosphomimetic
p53 mutant. However, one of the difficulties with studying p53
protein-protein interactions in the core DNA-binding domain
by mutation is that changes in the majority of codons “inacti-
vate” p53, making such an analyses difficult to interpret. Exam-
ination of codon 269 mutations in human cancers shows the
predominant changes, including Serine mutation to Thr, Ile,
Gly, Leu, Asn, Arg, and Cys (see the International Agency for
Research on Cancer Web site). Because these mutations are
presumably inactivating, we examined whether we could first
identify “neutral” mutations at codon 269 that do not inactivate
p53. The p53 mutant p53S269A did not lose activity; indeed, the
specific activity was elevated relative to wild type p53 as defined
by MDM2 protein induction (Fig. 9A, lane 4 versus lane 3) or
p21 protein induction (Fig. 9B, lane 4 versus lane 3). The
enhanced function of p53S269A was not observed using tran-
sient transfection of bax or p21 luc reporters; nevertheless, the
S269A mutant was as active as WT p53 (Fig. 9, C and D), indi-
cating that amutation does not a priori “inactivate” p53 protein
function.
As such,we also examinedwhether a phosphomimeticmuta-
tion at codon 269 would likewise stimulate, inactivate, or dem-
onstrate no change in p53 activity. The mutant p53S269D was
unable to induce MDM2 or p21 proteins (Fig. 9, A and B), sug-
gesting that adding a negative charge at codon 269 can inacti-
FIGURE 7. Serine 269-phosphorylated p53 has a selective subcellular localization. A, schematic representation of the fractionation methodology. B–D,
effects of irradiation on p53 phosphorylation at theDO-12 epitope inMCF7 cells. MCF-7 cells were untreated or irradiatedwithUVC andgrown for a further 6 h
before fractionation into cytosolic (C), membrane/organelle (M), and nuclear fractions (Nu). Fractions were resolved by electrophoresis and immunoblotting
with DO-1 (B) and DO-12 before (C) and after phosphatase treatment of the membrane (D) to define p53 localization. Band intensity was quantified by Scion
Image software, and the -fold increase in antibody signal followingUVC irradiation is indicatedbelowB andD, respectively. Equivalent sample loading is shown
by Coomassie staining of the various fractions (E), and fractionation of the distinct subcellular fractions was demonstrated by probing for known cytoplasmic
(Hsp90), membrane (E-cadherin), and nuclear (c-Jun) marker proteins (F, G, and H, respectively).
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vate wild type p53. These data suggest that Ser269 phosphoryla-
tion will most likely produce a functionally mutant wild type
p53 protein and therefore represent an inactivating phos-
phorylation. The transcriptional activities of p53S269D mutant
toward luciferase cassettes containing p21 and Bax promoter
elements were also tested. Transfection of the phosphomimetic
p53S269D mutant was unable to induce transcription from p21
and Bax promoter elements (Fig. 9, C and D). A clonogenic
assay was also used to evaluate whether the phosphomimetic
mutation altered WT p53 function. Compared with the wild
type or p53S269A, which exhibit growth-suppressing activities
(Fig. 10, B and C versusA), the S269Dmutation inactivated the
growth-suppressive function of p53 (Fig. 10,D versus B). These
cellular findings (Figs. 9 and 10) indicate that phosphomimetic
mutation of p53 at Ser269 inhibits WT p53 function and
together suggest that phosphorylation of p53 in vivo at serine
269 produces a pool of transcriptionally attenuated p53protein.
DISCUSSION
There is growing evidence that a majority of protein-protein
interactions in higher eukaryotes are regulated by intrinsically
disorderedmotifs (50). p53 protein has large regions containing
FIGURE 8. In vivo phosphorylation of p53 at serine 269; detection using phosphospecific antibodies. A, phosphospecific antibody generation to serine
269. Monoclonal antibodies (mAb 2.1, 3.1, and 4.1) were generated toward phospho-Ser269 peptides, and peptide ELISA was used to demonstrate the
phosphospecificity of the antibodies. A, i–iii, serine 269 mAb (i, mAb 2.1; ii, mAb 3.1; iii, mAb 4.1) epitopes were mapped via ELISA using an alanine scan
mutationofGRNpSFEVRphosphopeptide.B–D, Ser269-phosphospecificmAb2.1 can immunoprecipitate p53 fromMCF7 lysates followingDNAdamage.MCF7
cells were exposed to 5 grays of x-ray or 10 J cm2 UV irradiation, and induction of p53 protein levels was analyzed 6 h later by immunoblotting with DO-1 (B,
showing 10 g of cellular lysate probed with DO-1 (top) and -actin (bottom) as a loading control). Total p53 protein and Ser269-phosphorylated p53 were
isolated from these lysates by immunoprecipitation with DO-1 (C) or mAb 2.1 (D), respectively, and an increase in Ser269 phosphorylation can be detected (D,
lanes 4 and 6). Protein G beads were used as a control for both DO-1 andmAb 2.1 immunoprecipitation and are shown in D in lanesmarked withminus signs.
This increase in phosphorylation with phosphospecific antibody after irradiation is consistent with the pool of DO-12 non-reactive p53 protein in the nucleus
of cells after UV radiation (Fig. 7, C versusD). E–F, time scale of p53 Ser269 phosphorylation following DNA damage. MCF-7 cells were irradiated with 5 grays of
x-ray radiation and harvested at the indicated time points. Increases in total p53 (E) or phospho-Ser269 p53 (F) protein levels were determined by immuno-
blotting cellular lysateswithDO-1 (E) or immunoprecipitating phospho-Ser269 p53 from cellular lysates using proteinGbeadswithout () orwithmAb2.1 (),
followed by immunoblotting with polyclonal CM-1 (F). R.L.U., relative light units; IP, immunoprecipitation; IB, immunoblot.
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intrinsically unstructured motifs, and the core DNA-binding
domain is thermodynamically unstable. These regions regulate
protein-protein interactions that control p53 activity. One
recently identified conformationally flexiblemotif harbors both
the MDM2 ubiquitination signal and protein kinase docking
sites in the p53DNA-binding domain (Fig. 11). Thismultifunc-
tional protein interaction site thus
has a potential to play a fundamen-
tal role in p53 activation and its
inhibition. In order to determine
whether p53 is phosphorylated
within this multiprotein docking
site in the MDM2 ubiquitination
signal, we took advantage of a tool
involving kinase substrate profiling
to define the linear interaction
motifs that direct enzyme specificity
and substrate utilization. Here we
used chip peptide array technology
to expand substrate utilization of
the calmodulin kinase family mem-
bers, including DAPK and Chk2, to
define potential physiological phos-
phoacceptor consensus sites using
peptides from naturally occurring
proteins. PepChip technology has
been used to successfully character-
ize the complex changes that occur
within the epithelial esophageal
kinome during the early transitional
stages of carcinogenesis (27) and
map the cellular phosphoproteome
(28). After delineation of a novel
consensus phosphoacceptor site
coupled to homology searches for
similar motifs in the p53 DNA-
binding domain, we identified a
novel phosphorylation site in the S10 -sheet region of p53 at
Ser269. This region (Fig. 11) is notable in being (i) a site of con-
formational flexibility in mutant gain-of-function p53 (24); (ii)
the ubiquitin signal forMDM2-mediated ubiquitination of p53
(23); and (iii) a docking site for a range of protein kinases that
phosphorylate the transactivation domain of p53 (25). A range
of approaches were used to demonstrate that Ser269 phosphor-
ylation can occur on endogenous WT p53 in cells and that
phosphomimeticmutation results in the production of inactive
WT p53. An accompanying paper (51) describes the biophysi-
cal basis for p53 inactivation by phosphorylation of p53 at
Ser269 and involves primarily increases in the thermoinstability
of the core DNA-binding domain of p53. These data highlight
the existence of a novel kinase pathway that can regulate the
dynamic range of conformations in WT p53 and that can pro-
duce a mutant-like conformation on WT p53.
Most phosphorylation sites characterized to date play a role
in p53 activation. These include (i) phosphorylation in the
transactivation domain (the BOX-I domain) at Thr18 and Ser20,
which stabilizes the activator p300 (3, 4) and/or destabilizes the
inhibitory protein MDM2 (31, 52); (ii) phosphorylation at the
C-terminal CK2 site, which stimulates specific DNA binding
(42); (iii) PKC phosphorylation in the C terminus that can cre-
ate a 14-3-3 phosphopeptide binding motif and stimulate the
specific DNA binding function of p53 (53); and (iv) CDK phos-
phorylation at Ser315 after DNA damage that can stimulate the
specific DNA-binding function of p53 (49). There are also a
FIGURE 9. The effects of codon 269 mutation on p53 activity in cells; phosphomimetic substitution of
serine 269 inactivates p53. The effect of serine 269 mutation on expression of the p53 downstream target
genes,Mdm2 andp21, was examinedby immunoblotting20gof lysates derived fromH1299 cells transfected
with pcDNA vector control, wild type p53, p53S269A, or p53S269D mutants using the anti-MDM2 monoclonal
antibody 2A10 (A) or the p21 monoclonal antibody Ab-1 (B). C and D, p53 function from reporters containing
p53-responsive binding sites. H1299 cells were transfectedwith the p21 or Bax reporter plasmids alone orwith
(1–75 ng of) pExpr p53, S269A, or S269D expression vectors. Total DNA was normalized with pExpr vector
control plasmid DNA. Twenty-four hours later, cells were lysed, and luciferase activity from p21 (C) or Bax (D)
reporterswas determinedusing dual luciferase reporter assays. Datawere normalized by expressing luciferase
activity (luciferase/Renilla) in relative light units (R.L.U.). The lower panels depict p53 protein levels after trans-
fection by immunoblotting. GAPDH immunoblotting was used as a loading control.
FIGURE 10.Phosphomimeticmutation of Ser269 inhibits p53growth-sup-
pressive activity. H1299 cells were transfected with 1 g of pcDNA plasmid
containing wild type, S269A, or S269D. Twenty-four hours later, cells were
trypsinized and diluted and then plated in medium containing 0.5 mg/ml
Geneticin and grown for a further 2 weeks. Colonies were fixed and stained
with Giemsa dye.
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small growing number of phosphorylation events that are
linked to p53 inactivation. These include (i) phosphorylation by
the CK2 component of the COP9 signalosome that triggers p53
degradation (54); (ii) phosphorylation at Ser315 by a GSK3-de-
pendent pathway that can stimulate p53 nuclear export (55);
and (iii) phosphorylation by Aurora kinase at either Ser215 or
Ser315, which was reported to inactivate p53 by an undefined
mechanism (56, 57). Thus, despite the fact that there are a
growing number of inactivating phosphorylation sites on p53,
there are few mechanistic data on how this regulates protein-
protein interactions that lead to p53 inactivation. In this report,
in analyzing a novel phosphorylation site on p53 using aspar-
tate, phosphomimetic mutants, our data indicate that Ser269
phosphorylation would be inactivating with respect to p53-de-
pendent transcription and clonogenic suppression.
Wedo not know as of yet the physiological kinase that targets
the Ser269 site on p53 and whether DAPK or CHK1 could actu-
ally target Ser269 in vivo. Previous work on protein kinases have
shown dual functions: (i) the CK1 enzyme can either activate
p53 (via virus or TGF- pathway) (26, 58) or suppress p53 func-
tions (59, 60), depending upon the input signal, and (ii) the
same phosphorylation site on p53 (Ser315) can be activating
after DNA damage (CDK2) (49, 61) or inactivating in cycling
cells (by GSK3 or by Aurora) (55), suggesting that context is
important for kinase signaling. Thus, by this logic, if DAPK is a
Ser269 kinase in vivo, then it would be consistent with its previ-
ously defined dual function; DAPK can be activating for p53
with an ARF-oncogene signal input (62), but it could be inacti-
vating for p53 given an EGF input signal where DAPK inacti-
vates TSC2, resulting in mTOR stimulation (63). However, we
do not know that DAPK is the real in vivo kinase for Ser269.
DAPK is part of the calcium-calmodulin superfamily, which
can target theXSFXmotif (25) (Table 1). Thus, we do not know
that DAPK and CHK1 are, necessarily, the Ser269 kinases in
cells; this is the work we are currently investigating to see
whether the calcium-calmodulin superfamily or other families
represent the in vivo kinase for the Ser269 site.
The interesting feature of Ser269 phosphorylation is that,
although basal phosphorylation can be detected in a range of
tumor cell lineswith awild type p53 status, DNAdamages, such
as that induced by UV or x-rays, induce Ser269 phosphorylation
with kinetics that parallel p53 protein induction by DNA dam-
age. These data would suggest that Ser269-phosphorylated p53
would be in a transcriptionally inactive state. Reasons for
inducing this modification of p53 after DNA damage might
include the following: (i) cells need to make “inactive” mutant-
like WT p53 protein in order to begin to attenuate WT p53
functions and begin the process of regrowth after repairing
damaged DNA, and/or (ii) creating this inactive and unfolded
conformation to phospho-Ser269 p53 might begin the process
of p53 ubiquitination and degradation that occurs in undam-
aged as well as damaged cells. Although the mechanistic stages
that play a role in p53 ubiquitination and degradation in cells
are undefined, it is known that unfolded mutant p53 is more
prone to MDM2-dependent ubiquitination in vivo (64), and a
trimeric complex of MDM2-Hsp90-CHIP can unfold the WT
p53 tetramer in vitro (65).However, the ubiquitin ligaseCHIP is
also implicated in ubiquitination and degradation of mutant
p53 (34, 65). Such unfolding ofWTp53might play a role in how
it is ubiquitinated and/or degraded in vivo by many distinct
ubiquitin ligases. Thus, there are widespread implications for
the existence of cellular kinase pathways that can promoteWT
p53 inactivation by phosphorylation of this conformationally
flexible motif in the p53 DNA-binding domain. In an accompa-
nying paper (51), we report on the molecular basis for how p53
can be inactivated by Ser269 phosphorylation through the char-
acterization of aspartate phosphomimetic mutant and through
computational modeling. Our data suggest that Ser269 phos-
phorylation destabilizes the normal folding of the p53 DNA-
binding domain and provides a mechanism for cells to create a
mutant-like conformation to the WT p53 tetramer. Under-
standing the functions of phospho-Ser269 WT p53 in cells,
defining how the altered conformation of Ser269-phospho-p53
alters in the interactome of p53, and defining the kinase/phos-
phatase pathways that target this site on p53will begin to define
how this phosphorylation site regulates the activation and inac-
tivation of the p53 response.
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